2017 American Transplant Congress
A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus.
Hospital das Clinicas FMUSP, Sao Paulo, Brazil
Mycophenolic acid(MPA) PK, from enteric-coated mycophenolate sodium(EC-MPS) has a broad range of Tmax avoiding the use a single concentration to calculate the area-under-the-time-concentration curve(AUC). Either…2017 American Transplant Congress
Early Exposure of Everolimus with and without Calcineurin Inhibitors.
Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, SP, Brazil
This study aimed to evaluate the effect of cyclosporine (CSA) or tacrolimus (TAC) on early exposure of everolimus (EVR).A cohort of 306 kidney transplant recipients…2017 American Transplant Congress
Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.
1U of Cinicnnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3iC42 Clinical Research, Colorado
Tacrolimus (Tac) is a cornerstone immunosuppressant metabolized in the gut and liver, resulting in high intra/inter patient pharmacokinetic (PK) variability. Recipient genotype (RG) impacts tac…2016 American Transplant Congress
Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.
Introduction: Alemtuzumab induction followed by a steroid-free, tacrolimus (Tac) and mycophenolate mofetil (MMF) based regimen effectively prevented acute rejection after simultaneous pancreas-kidney transplantation (SPKT). Acute…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
Are Random Tacrolimus Levels in the Emergency Department Costing You Money?
University of Illinois at Chicago, Chicago.
Purpose: Tacrolimus (TAC) is the most frequently used immunosuppressant in the USA today, with a narrow therapeutic index that requires frequent 12-hour trough monitoring and…2016 American Transplant Congress
Pharmacokinetic Evaluation of Astagraf XL® and Prograf® in Renal Transplant Candidates Following Laparoscopic Sleeve Gastrectomy.
Purpose: The impact of laparoscopic sleeve gastrectomy (LGS) on immunosuppressive drug pharmacokinetics (PK) is unknown. The purpose of this study was to evaluate PK following…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »